Abstract
Loop CAR empowered both UCB-NK cells and hPSC-iNK cells with superior cytotoxicity against CD33<sup>+</sup>MSLN<sup>+</sup> tumor cells. Genetic disruption of CD33 avoided fratricide and improved efficacy of Loop CAR-iNK cells against AML. This innovative strategy possesses unique advantages and translational potential for treating AML.
Introduction
Acute myeloid leukemia (AML) remains a significant clinical challenge, particularly for elderly patients who cannot tolerate intensive chemotherapy or wait for the lengthy production cycles of autologous CAR-T cell therapies. Natural Killer (NK) cells have emerged as a promising "off-the-shelf" alternative. However, two primary obstacles hinder their effectiveness: fratricide and antigen escape.
Fratricide occurs when CAR-NK cells target markers like CD33, which are also expressed on healthy NK cells, leading to self-destruction. Antigen escape occurs when cancer cells downregulate a single target antigen to evade detection. This study introduces a novel "Loop CAR" design and CRISPR-mediated gene editing to overcome these hurdles.
Methods and Design
The researchers developed a bivalent "Loop CAR" architecture to simultaneously target CD33 and Mesothelin (MSLN). Unlike standard tandem designs, the Loop structure utilizes a specific spatial arrangement of variable light ($V_L$) and heavy ($V_H$) chains connected by a "whitlow" linker to optimize receptor clustering.
To eliminate fratricide, the team used CRISPR/Cas12i to knock out the CD33 gene in human pluripotent stem cells (hPSCs). These $CD33^{KO}$ hPSCs were then differentiated into mature NK cells (iNKs) using a specialized 3D organoid induction system. This approach ensures a scalable supply of standardized, "invisible" therapeutic cells that do not kill one another. The therapy was validated using established cell lines (Nomo-1, AGS, HL-60) and primary bone marrow samples from AML patients.
Key Results
Enhanced Cytotoxicity and Expansion
The Loop CAR design demonstrated superior receptor clustering and immunological synapse formation compared to single-target or tandem CARs. Crucially, the $CD33^{KO}$ modification successfully restored the expansion capacity of the NK cells, which was otherwise severely limited by self-killing. Without the knockout, population growth was stunted; with it, the cells expanded normally and showed higher specific cytotoxicity.
Efficacy Against Patient Samples
The optimized $CD33^{KO}$ Loop CAR-iNK cells showed significantly higher specific cytotoxicity against primary AML cells from patients compared to control groups, demonstrating the clinical relevance of the dual-targeting approach.
Improved Survival In Vivo
In mouse models of AML, the $CD33^{KO}$ Loop CAR-iNK treatment resulted in the most robust antitumor response. Mice treated with these optimized cells achieved a median survival of 42–46 days, a significant improvement over untreated mice (28–32 days) and those treated with standard CAR designs (34–38 days).
Discussion
This study highlights the importance of CAR architecture and genetic "shielding" in developing effective NK cell therapies. By targeting both CD33 and MSLN, the Loop CAR reduces the risk of antigen escape. While MSLN shedding remains a potential challenge for clinical translation, the dual-targeting strategy and the use of an hPSC-derived platform offer a potent, scalable solution for AML. Future work will focus on safety testing and exploring the potential of this design in solid tumors where MSLN is highly expressed, such as ovarian or pancreatic cancer.
Summary updated